Stock CGEN COMPUGEN LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Compugen Ltd.

Equities

CGEN

IL0010852080

Real-time Estimate Cboe BZX
Other stock markets
 15:57:12 02/05/2024 BST 		5-day change 1st Jan Change
2.06 USD +3.52% Intraday chart for Compugen Ltd. +7.89% +3.54%
03-08 Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating MT
03-05 Transcript : Compugen Ltd., Q4 2023 Earnings Call, Mar 05, 2024

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Compugen Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
Compugen Ltd. Announces Executive Changes
Sector Update: Health Care Stocks Stronger Late Afternoon
Sector Update: Health Care
Looming Inflation Data Stifle US Equity Futures Pre-Bell
Gilead Sciences, Compugen Sign Exclusive Licensing Deal for Pre-Clinical Immunotherapy Program; Compugen Shares Soar
Top Midday Gainers
Top Premarket Gainers
Compugen Will Be Eligible to Receive $10 Million Milestone Payment Upon Dosing of First Patient in Astrazeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Gilead Sciences, Inc. and Compugen Ltd. Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Compugen Gets Nasdaq Non-Compliance Notice on Minimum Bid Price Rule
Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer
Sector Update: Health Care Stocks Retreating Monday Afternoon
Compugen Gets Japanese Patent for Cancer Combination Therapy
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
Compugen Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Compugen Says European Patent Office Rules in Favor of Maintaining Claims to Patent on Cancer Treatment
Compugen Wins on PVRIG European Patent Opposition Pursued by GSK and a Third Party
Compugen Ltd. Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CGEN Stock
  4. News Compugen Ltd.
  5. Other languages